Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Journal of the American Society of Nephrology, 11/04/09
Lieberthal W et al. – Inhibition of mTOR by rapamycin or one of its analogues represents a potentially novel treatment for autosomal dominant polycystic kidney disease. Finally, inhibitors of mTOR improve survival in patients with metastatic renal cell carcinoma.
Related Articles
Cystic Changes of Breast in a Family With Autosomal Dominant Polycystic Kidney Disease
Iranian Journal of Kidney Diseases, 10/13/09
Relevance Score: 82%
Autosomal Dominant Polycystic Kidney Disease: Current and Emerging Treatments
Kidney, 10/30/09
Relevance Score: 81%
Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy
Kidney and Blood Pressure Research, 11/06/09
Relevance Score: 80%
Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1
Human Molecular Genetics, 11/03/09
Relevance Score: 80%
Psoas abscess in hemodialysis patients
International Urology and Nephrology, 10/06/09
Relevance Score: 80%
Today in Nephrology...keeping you current
Receive free subspecialty "5-minute updates" via email
Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial Cells
Journal of the American Society of Nephrology, 11/25/09
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Journal of the American Society of Nephrology, 11/25/09
25-Hydroxyvitamin D Levels, Race, and the Progression of Kidney Disease
Journal of the American Society of Nephrology, 11/25/09
Sponsor
Article Search
Sponsor


See Latest Articles


